LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients

BACKGROUND: The aim of this study was to investigate the association between LAPTM4B gene polymorphism and the risk of breast cancer among Egyptian female patients. Also, measurement was done of its serum level to evaluate its significance as a diagnostic marker for breast cancer. METHODS: This case...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaker, Olfat, Taha, Fatma, Salah, Maha, El-Marzouky, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Medical Biochemists of Serbia 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922358/
https://www.ncbi.nlm.nih.gov/pubmed/28356847
http://dx.doi.org/10.2478/jomb-2014-0067
_version_ 1782439611472019456
author Shaker, Olfat
Taha, Fatma
Salah, Maha
El-Marzouky, Mohamed
author_facet Shaker, Olfat
Taha, Fatma
Salah, Maha
El-Marzouky, Mohamed
author_sort Shaker, Olfat
collection PubMed
description BACKGROUND: The aim of this study was to investigate the association between LAPTM4B gene polymorphism and the risk of breast cancer among Egyptian female patients. Also, measurement was done of its serum level to evaluate its significance as a diagnostic marker for breast cancer. METHODS: This case control study was done on 88 breast cancer patients, 40 with fibroadenoma and 80 healthy subjects. Genotyping of the LAPTM4B polymorphism was determined by PCR. Serum LAPTM4B level was measured using ELISA. RESULTS: There was a significant difference in the (*1/2+ *2/2) genotypes in breast cancer patients (59.1) compared to the control subjects (43.8%) (P=0.047; OR=1.86; 95% CI =1.01–3.43). The frequency of the allele 2* of the LAPTM4B gene was significantly higher in breast cancer patients (36.4%) than in the control (25.6%) (p=0.034; OR=1.66; 95% CI =1.04–2.65). Genotypes (*1/2+*2/2) were significantly associated with the differential classification of TNM. Serum level of LAPTM4B was significantly higher in breast cancer patients than in control and fibroadenoma and in fibroadenoma patients than in control. In breast cancer patients, serum LAPTM4B was significantly higher in stage III and in large tumor size. Serum LAPTM4B was significantly higher in the cancer patients’ genotypes (*1/2+*2/2). CONCLUSIONS: Genetic polymorphism of LAPTM4B is a potential risk factor for the development of breast cancer. Serum LAPTM4B may be used as a diagnostic and prognostic marker for breast cancer.
format Online
Article
Text
id pubmed-4922358
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Society of Medical Biochemists of Serbia
record_format MEDLINE/PubMed
spelling pubmed-49223582017-03-29 LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients Shaker, Olfat Taha, Fatma Salah, Maha El-Marzouky, Mohamed J Med Biochem Original Paper BACKGROUND: The aim of this study was to investigate the association between LAPTM4B gene polymorphism and the risk of breast cancer among Egyptian female patients. Also, measurement was done of its serum level to evaluate its significance as a diagnostic marker for breast cancer. METHODS: This case control study was done on 88 breast cancer patients, 40 with fibroadenoma and 80 healthy subjects. Genotyping of the LAPTM4B polymorphism was determined by PCR. Serum LAPTM4B level was measured using ELISA. RESULTS: There was a significant difference in the (*1/2+ *2/2) genotypes in breast cancer patients (59.1) compared to the control subjects (43.8%) (P=0.047; OR=1.86; 95% CI =1.01–3.43). The frequency of the allele 2* of the LAPTM4B gene was significantly higher in breast cancer patients (36.4%) than in the control (25.6%) (p=0.034; OR=1.66; 95% CI =1.04–2.65). Genotypes (*1/2+*2/2) were significantly associated with the differential classification of TNM. Serum level of LAPTM4B was significantly higher in breast cancer patients than in control and fibroadenoma and in fibroadenoma patients than in control. In breast cancer patients, serum LAPTM4B was significantly higher in stage III and in large tumor size. Serum LAPTM4B was significantly higher in the cancer patients’ genotypes (*1/2+*2/2). CONCLUSIONS: Genetic polymorphism of LAPTM4B is a potential risk factor for the development of breast cancer. Serum LAPTM4B may be used as a diagnostic and prognostic marker for breast cancer. Society of Medical Biochemists of Serbia 2015-10 2015-09-19 /pmc/articles/PMC4922358/ /pubmed/28356847 http://dx.doi.org/10.2478/jomb-2014-0067 Text en © 2015 Olfat Shaker et al., published by De Gruyter Open http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Paper
Shaker, Olfat
Taha, Fatma
Salah, Maha
El-Marzouky, Mohamed
LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
title LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
title_full LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
title_fullStr LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
title_full_unstemmed LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
title_short LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
title_sort laptm4b gene expression and polymorphism as diagnostic markers of breast cancer in egyptian patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922358/
https://www.ncbi.nlm.nih.gov/pubmed/28356847
http://dx.doi.org/10.2478/jomb-2014-0067
work_keys_str_mv AT shakerolfat laptm4bgeneexpressionandpolymorphismasdiagnosticmarkersofbreastcancerinegyptianpatients
AT tahafatma laptm4bgeneexpressionandpolymorphismasdiagnosticmarkersofbreastcancerinegyptianpatients
AT salahmaha laptm4bgeneexpressionandpolymorphismasdiagnosticmarkersofbreastcancerinegyptianpatients
AT elmarzoukymohamed laptm4bgeneexpressionandpolymorphismasdiagnosticmarkersofbreastcancerinegyptianpatients